Low-Dose Lithium for Parkinson's Disease
Also known as: Lithium orotate, Lithium aspartate, Microdose lithium
GSK3β inhibition by lithium may reduce α-synuclein phosphorylation and protect dopaminergic neurons.
Mechanism of Action
Lithium's GSK3β inhibition reduces α-synuclein phosphorylation at Ser129 (associated with toxicity). It induces autophagy for α-synuclein aggregate clearance and enhances GDNF expression for dopaminergic neuron trophic support.
General mechanism: GSK3β inhibitor. Autophagy inducer (IP3 pathway). BDNF/GDNF enhancer. Neuroprotective at microdoses.
Current Evidence
Preclinical models show dopaminergic neuroprotection with lithium. Clinical application limited by therapeutic index concerns. Microdose approach may resolve safety issues.
Clinical Status: Preclinical support. Microdose approach under investigation.
Safety Profile
Microdose (<1mg): very safe. Standard dose (600-1200mg): renal, thyroid toxicity requiring monitoring. Narrow therapeutic index at psychiatric doses.
Key Research Questions
- Can microdose lithium reduce α-synuclein pathology in PD?
- Does lithium's GDNF induction protect dopaminergic neurons at sub-therapeutic doses?